Sichuan Kelun Pharmaceutical Co Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sichuan Kelun Pharmaceutical Co Ltd.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.
ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets
Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.
Opportunities Amid Crisis: Junshi, Allist Look To Expand Pipelines Through Alliances, M&A
Against the prevailing headwinds in the biotech sector, two Chinese firms are bucking the trend of pipeline reorganization by eyeing the potential acquisition of assets from external partners to expand into more modalities and therapeutic areas.
Alentis Adds To Bank Balance And Rides The Claudin Wave
While most of the R&D attention in the hot space of claudins has focused on targeting CLDN18.2, the Swiss biotech believes its CLDN1 programs have the advantage of a broader expression profile.
- Generic Drugs
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Guangxi Kelun Pharmaceutical Co Ltd
- Hunan Kelun Pharmaceutical Co Ltd
- Hubei Kelun Pharmaceutical Co Ltd
- Kelun Pharmaceutical Group
- KLUS Pharma Inc
- Shandong Kelun Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Research Co Ltd
- Suzhou Kelun Pharmaceutical Research Co Ltd
- Sichuan Xindi Pharmaceutical Chemicals Co Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.